ALX Oncology and Quantum Leap Healthcare Collaborative announced that the first patient has been dosed in the I-SPY-P1-TRIAL for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer. Sponsored by Quantum Leap, this Phase 1, multi-center study arm will investigate evorpacept, a CD47 blocker, in combination with ENHERTU, a HER2 directed antibody-drug conjugate, to determine the safety, tolerability and efficacy of this drug combination.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALXO:
- ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer
- ALX Oncology price target lowered to $30 from $65 at H.C. Wainwright
- ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones
- ALX Oncology announces first patient dosed in ASPEN-07 study
- ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer
